Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada

Dupilumab, omalizumab, and mepolizumab are the three biologics currently approved for use in CRSwNP in Canada. Despite evidence of efficacy, their cost-effectiveness, which is a key factor influencing prescrib...

Source: Allergy, Asthma and Clinical Immunology - October 14, 2023 Category: Allergy & Immunology Authors: Michael Yong, Keshinisuthan Kirubalingam, Martin Y. Desrosiers, Shaun J. Kilty and Andrew Thamboo Tags: Research Source Type: research